Responder analyses for anti-amyloid immunotherapies for Alzheimer's disease: a paradigm shift by regulatory authorities is urgently needed
Brain Commun
.
2023 Oct 24;5(5):fcad276.
doi: 10.1093/braincomms/fcad276.
eCollection 2023.
Authors
Simone Salemme
1
,
Antonio Ancidoni
2
3
,
Nicola Vanacore
2
Affiliations
1
Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy.
2
National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome 00161, Italy.
3
Department of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy.
PMID:
37901042
PMCID:
PMC10612473
DOI:
10.1093/braincomms/fcad276
No abstract available